Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25189982 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Philippe Decruyenaere und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ghent University Hospital, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Cyclophosphamide, Vincristine, Transcriptome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation - Flanders, Baekeland mandate, Ghent University.
Abstract (Originalsprache)
The potential of RNA-based liquid biopsy is increasingly being recognized in diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin’s lymphoma. This study explores the cell-free transcriptome in a humanized DLBCL patient-derived tumor xenograft (PDTX) model. Blood plasma samples (n = 171) derived from a DLBCL PDTX model, including 27 humanized (HIS) PDTX, 8 HIS non-PDTX, and 21 non-HIS PDTX non-obese diabetic (NOD)-scid IL2Rgnull (NSG) mice were collected during humanization, xenografting, treatment, and sacrifice. The mice were treated with either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), CD20-targeted human IFNα2-based AcTaferon combined with CHOP (huCD20-Fc-AFN-CHOP), or phosphate-buffered saline (PBS). RNA was extracted using the miRNeasy serum/plasma kit and sequenced on the NovaSeq 6000 platform. RNA sequencing data of the formalin-fixed paraffin-embedded (FFPE) tissue and blood plasma samples of the original patient were included. Flow cytometry was performed on immune cells isolated from whole blood, spleen, and bone marrow. Bulk deconvolution was performed using the Tabula Sapiens v1 basis matrix. Both R-CHOP and huCD20-Fc-AFN-CHOP were able to control tumor growth in most mice. Xenograft tumor volume was strongly associated with circulating tumor RNA (ctRNA) concentration (p < 0.001, R = 0.89), as well as with the number of detected human genes (p < 0.001, R = 0.79). Abundance analysis identified tumor-specific biomarkers that were dynamically tracked during tumor growth or treatment. An 8-gene signature demonstrated high accuracy for assessing therapy response (AUC 0.92). The tumoral gene detectability in the ctRNA of the PDTX-derived plasma was associated with RNA abundance levels in the patient’s tumor tissue and blood plasma (p < 0.001), confirming that tumoral gene abundance contributes to the cell-free RNA (cfRNA) profile. Decomposing the transcriptome, however, revealed high inter- and intra-mouse variability, which was lower in the HIS PDTX mice, indicating an impact of human engraftment on the stability and profile of cfRNA. Immunochemotherapy resulted in B cell depletion, and tumor clearance was reflected by a decrease in the fraction of human CD45+ cells. Lastly, bulk deconvolution provided complementary biological insights into the composition of the tumor and circulating immune system. In conclusion, the blood plasma-derived transcriptome serves as a biomarker source in a preclinical PDTX model, enables the assessment of biological pathways, and enhances the understanding of cfRNA dynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Ghent University Hospital, 9000 Ghent, Belgium.
- OncoRNALab, Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
- Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.
- Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
- VIB-UGent Center for Medical Biotechnology, 9052 Ghent, Belgium.
- Orionis Biosciences B.V., 9052 Zwijnaarde, Belgium.
ORCID-Profile: Philippe Decruyenaere, Willem Daneels, Annelien Morlion, Jasper Anckaert, Jo Vandesompele
Förderung
- Research Foundation - Flanders
- Baekeland mandate
- Ghent University
- Fund for Scientific Research Flanders
Zitieren
APA
Decruyenaere, P., Daneels, W., Morlion, A., Verniers, K., Anckaert, J., Tavernier, J., Offner, F., & Vandesompele, J. (2024). Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25189982
Vancouver
Decruyenaere P, Daneels W, Morlion A, Verniers K, Anckaert J, Tavernier J, et al. Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25189982
BibTeX
@article{Decruyenaere2024,
author = {Decruyenaere, Philippe and Daneels, Willem and Morlion, Annelien and Verniers, Kimberly and Anckaert, Jasper and Tavernier, Jan and Offner, Fritz and Vandesompele, Jo},
title = {Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25189982}
}
EUVIMED